- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03633461
Evaluation of the Efficacy of OC-02 Nasal Spray on Signs and Symptoms of Dry Eye Disease (the RAINIER Study)
February 25, 2022 updated by: Oyster Point Pharma, Inc.
Multicenter, Randomized, Controlled, Double-Masked Clinical Trial to Evaluate the Efficacy of OC-02 Nasal Spray on Signs and Symptoms of Dry Eye Disease (the RAINIER Study)
The objective of this study is to evaluate the safety and effectiveness of OC-02 nasal spray compared to placebo on signs and symptoms of dry eye disease (DED).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This was a Phase 2, multicenter, randomized, double-masked, placebo-controlled study designed to evaluate the safety and efficacy of OC-02 Nasal Spray in adult subjects with dry eye disease.
Approximately 45 subjects, at least 22 years of age, with a history of dry eye disease and meeting all other study eligibility criteria were planned to be randomized to receive an application of OC-02 or placebo twice daily (BID) for 4 weeks.
Study Type
Interventional
Enrollment (Actual)
53
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Kentucky
-
Louisville, Kentucky, United States, 40206
- Louisville
-
-
Tennessee
-
Nashville, Tennessee, United States, 37205
- Nashville
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Have used and/or desired to use an artificial tear substitute for dry eye symptoms within 60 days prior to Visit 1
Exclusion Criteria:
- Have had any intraocular surgery (such as cataract surgery), extraocular surgery (such as blepharoplasty) in either eye within three months or refractive surgery (e.g. laser epithelial keratomileusis, laser-assisted in-situ keratomileusis, photorefractive keratectomy or corneal implant) within twelve months of Visit 1
- Have a history or presence of any ocular disorder or condition in either eye that would, in the opinion of the Investigator, likely interfere with the interpretation of the study results or participant safety such as significant corneal or conjunctival scarring; pterygium or nodular pinguecula; current ocular infection, conjunctivitis, or inflammation not associated with dry eye; anterior (epithelial) basement membrane corneal dystrophy or other clinically significant corneal dystrophy or degeneration; ocular herpetic infection; evidence of keratoconus; etc. Blepharitis not requiring treatment and mild meibomian gland disease that are typically associated with dry eye disease are allowed.
- Have a systemic condition or disease not stabilized or judged by the Investigator to be incompatible with participation in the study or with the lengthier assessments required by the study (e.g., current systemic infection, uncontrolled autoimmune disease, uncontrolled immunodeficiency disease, history of myocardial infarction or heart disease, etc.)
- Have a known hypersensitivity to any of the procedural agents or study drug components
- Have any condition or history that, in the opinion of the investigator, may interfere with study compliance, outcome measures, safety parameters, and/or the general medical condition of the subject
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: OC-02 (simpinicline) spray spray, 11.1 mg/ml
OC-02 (simpinicline) nasal spray, 11.1 mg/ml
|
OC-02 (simpinicline) nasal spray, 11.1 mg/ml
Other Names:
|
Placebo Comparator: Placebo
Placebo (vehicle) nasal spray
|
Placebo (vehicle) nasal spray
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Change in Schirmer's Test From Baseline to 28 Days
Time Frame: 28 days [Visit 1 (baseline) and Visit 5 (28 Days)]
|
The primary end point was the change in anesthetized Schirmer's Test Score (STS) from baseline to 28 days in the study eye following treatment with OC-02.
Schirmer's test score from 0-35 mm where a higher score is indicative of a better outcome.
|
28 days [Visit 1 (baseline) and Visit 5 (28 Days)]
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 14, 2018
Primary Completion (Actual)
September 20, 2018
Study Completion (Actual)
September 20, 2018
Study Registration Dates
First Submitted
August 14, 2018
First Submitted That Met QC Criteria
August 14, 2018
First Posted (Actual)
August 16, 2018
Study Record Updates
Last Update Posted (Actual)
March 9, 2022
Last Update Submitted That Met QC Criteria
February 25, 2022
Last Verified
February 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- OPP-003
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dry Eye Disease
-
Bausch & Lomb IncorporatedCompletedDry Eye Disease (DED)United States
-
Gordon Schanzlin New VisionCompletedDry Eye | Dry Eye Disease | Evaporative Dry Eye | Kerato Conjunctivitis Sicca | Evaporative Dry Eye Disease | Dry Eye, EvaporativeUnited States
-
Laboratorios Sophia S.A de C.V.Not yet recruitingOcular Surface Disease | Dry Eye Disease | Dry Eye Sensation
-
Senju Pharmaceutical Co., Ltd.CompletedDry Eye Syndrome | Dry Eye DiseaseUnited States
-
AllerganCompletedDry Eye Syndrome | Dry Eye DiseaseUnited States
-
LantibioRiver Plate Biotechnology, Inc.; Rx Development Resources, LLCCompletedSafety and Efficacy Assessment of Vismed® (Sodium Hyaluronate) for the Treatment of Dry Eye SyndromeDry Eye DiseaseUnited States
-
Fundación Oftalmológica Los AndesAlcon ResearchNot yet recruitingCataract | Dry Eye Syndrome | Dry Eye Disease | Phacoemulsification | Evaporative Dry Eye
-
Vienna Institute for Research in Ocular SurgeryTerminated
-
Novaliq GmbHCompletedDry Eye Disease (DED)United States
-
Novaliq GmbHCompletedDry Eye Disease (DED)United States
Clinical Trials on Placebo (vehicle) nasal spray
-
Alcon ResearchCompleted
-
VistaGen Therapeutics, Inc.TerminatedSocial Anxiety DisorderUnited States
-
VistaGen Therapeutics, Inc.RecruitingSocial Anxiety DisorderUnited States
-
VistaGen Therapeutics, Inc.CompletedSocial Anxiety DisorderUnited States
-
University of ChicagoMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.Withdrawn
-
Chulalongkorn UniversityNot yet recruiting
-
University Hospital, AntwerpUnknownChronic Rhinosinusitis (Diagnosis) | Probiotics | Healthy Volunteers | Nasal Disease | SpraysBelgium
-
Sara EspinozaThe University of Texas Health Science Center, Houston; The University of Texas... and other collaboratorsCompletedObesity | Sedentary Lifestyle | Sarcopenia | Aging | Sarcopenic ObesityUnited States
-
Beijing Ditan HospitalCompleted
-
Oyster Point Pharma, Inc.CompletedDry Eye Disease (DED)United States